NCT05620823: An ongoing trial by Incyte Corporation
This trial is ongoing. It must report results 1 month, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05620823 |
|---|---|
| Title | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 19, 2022 |
| Completion date | Feb. 3, 2025 |
| Required reporting date | Feb. 3, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |